Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: A post-marketing analysis

Journal of Clinical Lipidology

Volumn 3, Issue 2, 2009, Pages 138-142

  Alsheikh Ali, Alawi A ^a   Karas, Richard H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse event; Cancer; Cholesterol; Ezetimibe; Statin

Indexed keywords

ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADVERSE OUTCOME; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; DIGESTIVE SYSTEM CANCER; DRUG INDUCED CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LUNG CANCER; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SKIN CANCER;

EID: 62349126043     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.02.005     Document Type: Article

References (23)

1. Rossebo A.B., Pedersen T.R., Boman K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359 (2008) 1343-1356
2. Peto R., Emberson J., Landray M., et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 359 (2008) 1357-1366
3. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443
4. Alsheikh-Ali A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50 (2007) 409-418
5. Alsheikh-Ali A.A., Abourjaily H.M., and Karas R.H. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). Am J Cardiol 89 (2002) 1308-1310
6. Abourjaily H.M., Alsheikh-Ali A.A., and Karas R.H. Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin. Am J Cardiol 91 (2003) 999-1002
7. Alsheikh-Ali A.A., and Karas R.H. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones. Am J Cardiol 93 (2004) 1417-1418
8. Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. Risk of adverse events with fibrates. Am J Cardiol 94 (2004) 935-938
9. Alsheikh-Ali A.A., Ambrose M.S., Kuvin J.T., and Karas R.H. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 111 (2005) 3051-3057
10. Alsheikh-Ali A.A., and Karas R.H. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 8 (2005) 95-97
11. Alsheikh-Ali A.A., and Karas R.H. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 99 (2007) 379-381
12. Holoshitz N., Alsheikh-Ali A.A., and Karas R.H. Relative safety of gemfibrozil and fenofibrate in the absence of conocmitant cerivastatin use. Am J Cardiol 101 (2008) 95-97
13. Jacobs D., Blackburn H., Higgins M., et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation 86 (1992) 1046-1060
14. Alsheikh-Ali A.A., Trikalinos T.T., Kent D.M., and Karas R.H. Statins, low-density lipoprotein cholesterol and risk of cancer. J Am Coll Cardiol 52 (2008) 1141-1147
15. Bjerre L.M., and LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 110 (2001) 716-723
16. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
17. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., and White C.M. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74-80
18. Zetia (ezetimibe) package insert. North Wales, PA, Merck/Schering-Plough Pharmaceuticals, 2007.
19. Begaud B., Martin K., Haramburu F., and Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 288 (2002) 1588
20. Weber J.C.P. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. Advances in inflammation research (1984), Raven Press, New York, NY 1-7
21. Hartnell N.R., and Wilson J.P. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 24 6 (2004) 743-749
22. Rossi A.C., Knapp D.E., Anello C., et al. Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. JAMA 249 (1983) 2226-2228
23. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540